Longitudinal Studies of Patient With FPDMM
National Human Genome Research Institute (NHGRI) · NCT03854318
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 0 mo–100 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 1000
- US sites recruiting
- 1
- Study start
- March 28, 2019
- Record last updated
- October 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Background
Genes tell the body and its cells how to work. Familial platelet disease (FPD) or FPD with associated malignancies (FPDMM) is caused by a variant in the gene RUNX1. People with this disease may have problems with their blood and bleed for a long time when they are injured. Researchers want to learn more about RUNX1 variants and FPD.
Objective
To learn more about FPD in people with RUNX1 variants to lead to better diagnosis, monitoring, and treatment.
Eligibility
People any age with a suspected or confirmed RUNX1 variant
People who have a family member with the variant
Design
All participants will be screened with a phone call and a blood, saliva, or cheek cell sample.
Participants with a suspected or confirmed variant will have 1 visit. It will last about 2 days. They will then have visits at least once a year.
Visits will include
- Medical history and physical exam
- Blood tests or saliva sample
- Possible skin biopsy: A small piece of the participant s skin will be removed.
- Bone marrow aspiration or biopsy: The participant s bone marrow will be removed by needle from a large bone such as the hip bone.
- Possible apheresis: Blood will be removed from the body and certain blood cells will be taken out. The rest of the blood is returned to the body.
Between visits, participants with a suspected or confirmed variant will keep a diary of disease symptoms and signs.
Samples from all participants may be used for genetic testing
Conditions: Inherited Hematological Diseases; Rare Diseases; FPDMM
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
- INCLUSION CRITIERIA:
Patients enrolled in this protocol will have been referred with a known or suspected variant in the RUNX1 gene. Patients with suspected RUNX1 variants are those with clinical features of FPD but who have not been tested for RUNX1, or who were negative on standard testing. The Principal Investigator, along with consulting specialists, will review the medical records of prospective patients and offer enrollment based upon the potential to help the individual, to learn from the patient, or to initiate clinical or basic research suggested by the patient's workup. Persons interested in participation may be given a screening questionnaire to determine eligibility. The questions about hematologic manifestations in the screening questionnaire are important to help us determine if RUNX1 variants are likely to be pathogenic, or if there is a high clinical suspicion of RUNX1 (abnormal platelets, bleeding, bruising, leukemia etc.). Unaffected family members may be asked to enroll in the study to provide specimens (saliva, blood, skin) for genetic testing, next-generation sequencing, and other related studies. Enrolled subjects can be any sex and any age. There are no upper or lower age restrictions on this study.
EXCLUSION CRITIERIA
There are no exclusionary criteria.
Recruiting US locations
National Institutes of Health Clinical Center
Bethesda, MD 20892
Site contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · 800-411-1222 · ccopr@nih.gov
Study contacts (from the official record)
- Natalie T Deuitch · (301) 385-5205 · natalie.deuitch@nih.gov
- Paul Liu, M.D. · (301) 402-2529 · pliu@nhgri.nih.gov
Similar studies in Maryland
All healthy volunteers studies in Maryland →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Brooklyn, MD + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Location
- Bethesda, MD
- Eligibility basics
- Ages 21–60
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Study of Intravenous ZMA001 in Healthy Subjects
National Heart, Lung, and Blood Institute (NHLBI)
- Location
- Bethesda, MD
- Eligibility basics
- Ages 18–60
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
The Impact of Product Formulation on the Pharmacokinetics and Pharmacodynamics of Cannabis Edibles
Johns Hopkins University
- Location
- Baltimore, MD
- Eligibility basics
- Ages 21–55